|1.||Woisetschläger, Maximilian: 3 articles (07/2009 - 03/2006)|
|2.||Harrer, Nathalie: 2 articles (08/2008 - 03/2006)|
|3.||Neruda, Wolfgang: 2 articles (08/2008 - 03/2006)|
|4.||Bunaciu, Rodica P: 1 article (01/2015)|
|5.||Schaefer, Deanna M W: 1 article (01/2015)|
|6.||Yen, Andrew: 1 article (01/2015)|
|7.||Ibabao, Christopher N: 1 article (01/2015)|
|8.||Carballido, José M: 1 article (08/2012)|
|9.||Sarfati, Marika: 1 article (08/2012)|
|10.||Regairaz, Camille: 1 article (08/2012)|
08/15/2008 - "VAF347 is a low-molecular-weight compound that inhibits allergic lung inflammation in vivo. "
03/15/2006 - "The biological effects in vivo are most likely mediated by the immunoregulatory role of VAF347 on DCs because allergic lung inflammation was also inhibited in B-cell-deficient mice. "
07/01/2009 - "AhR signaling induced by the newly described ligand VAF347 inhibits allergic lung inflammation as well as suppresses pancreatic islet allograft rejection. "
08/15/2008 - "Functional AhR is responsible for the biologic activity of VAF347 because (1) other AhR agonists display an identical activity profile in vitro, (2) gene silencing of wild-type AhR expression or forced overexpression of a trans-dominant negative AhR ablates VAF347 activity to inhibit cytokine induced IL-6 expression in a human monocytic cell line, and (3) AhR-deficient mice are resistant to the compound's ability to block allergic lung inflammation in vivo. "
03/15/2006 - "In a mouse model of antigen-induced eosinophilic inflammation, VAF347 blocked lung eosinophilia, mucus hyperplasia, and serum IgE levels, representing the hallmarks of allergic lung inflammation. "
|2.||Interleukin-6 (Interleukin 6)
|3.||Tretinoin (Retinoic Acid)
|4.||Immunoglobulin E (IgE)
|1.||Homologous Transplantation (Allograft)